Open AccessAlpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA ‐Mutated HR +/ HER2 – Advanced Breast Cancer
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13662
Subject(s) - letrozole , medicine , breast cancer , cyclin dependent kinase , oncology , aromatase inhibitor , cdk inhibitor , cancer , pharmacology , aromatase , cell cycle
Treatment with alpelisib and letrozole appears to be effective in patients with HR‐positive, HER2‐negative, PIK3CA ‐mutated advanced breast cancer previously treated with a CDK 4/6 inhibitor, according to updated findings from the phase II BYLieve trial.